GlassScriptPhysician profile
Stephen Brown
NPI 1073274163
$7,216.33
in general payments reported to CMS, 2019-2025
31 companies · $2,915 in 2025
The $2,915 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,781 · 2024: $2,520 · 2025: $2,915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,165 · Education: $51.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,164.97 |
| Education | $51.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,090.76 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $990.88 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $797.40 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $699.75 | 2023-2025 | |
| Corcept Therapeutics | $434.41 | 2023-2025 | Korlym |
| Amgen INC. | $326.83 | 2023-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $312.95 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $300.03 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $291.94 | 2023-2025 | |
| Exact Sciences Corporation | $231.51 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $231.44 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Phathom Pharmaceuticals, INC. | $225.82 | 2024-2025 | Voquezna |
| Esperion Therapeutics, INC. | $177.42 | 2023-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.47 | 2023-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $128.20 | 2024-2025 | Spravato |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $115.95 | 2025 | Urolift |
| Otsuka America Pharmaceutical, INC. | $93.28 | 2025 | Abilify Asimtufii |
| Xeris Pharmaceuticals, INC. | $78.95 | 2025 | Gvoke Hypopen, Recorlev |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.45 | 2025 | Caplyta |
| Boston Scientific Corporation | $65.96 | 2024-2025 | Watchman Access System |
| Opko Pharmaceuticals, LLC | $51.36 | 2024-2025 | Rayaldee |
| Aimmune Therapeutics, INC. | $50.07 | 2024-2025 | Zenpep |
| Optinose US, INC. | $47.02 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $44.68 | 2023 | Quviviq |
| Dexcom, INC. | $44.53 | 2023-2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $36.77 | 2024-2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $31.65 | 2023 | Livalo |
| E.R. Squibb & Sons, L.L.C. | $29.92 | 2023-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.20 | 2024 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $16.85 | 2024 | Crysvita |
| Actelion Pharmaceuticals US, INC. | $15.88 | 2024 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.